Cost analysis of schizophrenia treatment with second-generation antipsychotic medications in North Carolina's Medicaid program

Journal of the American Pharmacists Association

Volumn 47, Issue 1, 2007, Pages 77-81

  Liu, Gordon G ^a   Sun, Shawn X ^b   Christensen, Dale B ^c   Zhao, Zhongyun ^d  

^a Peking University   (China)

^b Walgreens Health Services   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic agents (second generation); Cost analysis; Medicaid; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; COST; COST OF ILLNESS; ECONOMICS; FACTUAL DATABASE; FEMALE; HUMAN; MALE; MEDICAID; MIDDLE AGED; SCHIZOPHRENIA; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COST OF ILLNESS; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MEDICAID; MIDDLE AGED; NORTH CAROLINA; RISPERIDONE; SCHIZOPHRENIA;

EID: 33947516584     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/1544-3191.47.1.77.Liu     Document Type: Article

References (22)

1. Ashcroft DM, Frischer M, Lockett J, Chapman SR. Variations in prescribing atypical antipsychotic drugs in primary care: cross-sectional study. Pharmacoepidemiol Drug Saf. 2002;11:285-9.
2. Hermann RC, Yang DW, Ettner SL, et al. Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiatr Serv. 2002;53:425-30.
3. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25-40.
4. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychol. 1997;154:457-65.
5. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychol. 2002;159:1018-28.
6. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychol. 2002;159:255-62.
7. Nightengale BS, Crumly JM, Liao J, et al. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone. Psychopharmacol Bull. 1998;34:373-82.
8. Hamilton SH, Revicki DA, Edgell ET, et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. Pharmacoeconomics. 1999;15:469-80.
9. Shermock KM, Sadik MK, Kozma CM, et al. Risperidone, haloperidol and clozapine in the South Carolina Medicaid program: a comparative analysis of utilization and expenditure. Dis Manage Health Outcomes. 2001;9:203-13.
10. Gianfrancesco F, Durkin MB, Mahmoud R, et al. Use of health care services by patients treated with risperidone versus conventional antipsychotic agents. Pharmacoeconomics. 2002;20:413-27.
11. Schiller MJ, Shumway M, Hargreaves WA. Treatment costs and patient outcomes with use of risperidone in a public mental health setting. Psychiatr Serv. 1999;50:228-32.
12. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophreia: a randomized controlled trial. JAMA. 2003;26:2693-702.
13. Liu GG, Sun SX, Christensen DB, et al. Cost comparisons of olanzapine and risperidone in treating schizophrenia. Ann Pharmacother. 2004;38:134-41.
14. Jayaram M, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev. 2006(Apr 19);(2):CD005237.
15. Barbui C, Lintas C, Percudani M. Head to head comparison of the costs of atypical antipsychotics a systematic review. CNS Drugs. 2005;19:935-50.
16. Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health. 1999;20:125-44.
17. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ. 1999;18:153-71.
18. Bouckaert A, Crott R. The difference in mean costs as a pharmacoeconomic outcome variable: power considerations. Control Clin Trials. 1997;18:58-64.
19. Gilmore TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychol. 2004;161:692-9.
20. Anis AH, Carruthers SG, Carter AO, Kierulf J. Variability in prescription drug utilization: issues for research. CMAJ 1996 154: 635-40.
21. Wennberg DE. Variation in the delivery of health care: the stakes are high. Ann Intern Med. 1998; 128: 866-8.
22. Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia. Pharmacoeconomics. 2003;21:683-97.